Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma

Davina C.M. Simoes, Theodoros Vassilakopoulos, Dimitrios Toumpanakis, Kalomira Petrochilou, Charis Roussos, Andreas Papapetropoulos

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Rationale: The angiopoietins (Ang) comprise a family of growth factors mainly known for their role in blood vessel formation and remodeling. The best-studied member, Ang-1, exhibits antiapoptotic and antiinflammatory effects. Although the involvement of Ang-1 in angiogenesis is well recognized, little information exists about its role in respiratory physiology and disease. On the basis of its ability to inhibit vascular permeability, adhesion molecule expression, and cytokine production, we hypothesized that Ang-1 administration might exert a protective role in asthma. Objectives: To determine changes in the expression of Ang and to assess the ability of Ang-1 to prevent the histologic, biochemical,and functional changes observed in an animal model of asthma. Methods: To test our hypothesis, a model of allergic airway disease that develops after ovalbumin (OVA) sensitization and challenge was used. Measurements and Main Results: Ang-1 expression was reduced at the mRNA and protein levels in lung tissue of mice sensitized and challenged with OVA, leading to reduced Tie2 phosphorylation. Intranasal Ang-1 treatment prevented the OVA-induced eosinophilic lung infiltration, attenuated the increase in IL-5 and IL-13, and reduced eotaxin and vascular cell adhesion molecule 1 expression. These antiinflammatory actions of Ang-1 coincided with higher levels of IκB and decreased nuclear factor-κB binding activity. More importantly, Ang-1 reversed the OVA-induced increase in tissue resistance and elastance, improving lung function. Conclusions: We conclude that Ang-1 levels are decreased in asthma and that administration of Ang-1 might be of therapeutic value because it prevents the increased responsiveness of the airways to constrictors and ameliorates inflammation.

Original languageEnglish (US)
Pages (from-to)1314-1321
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume177
Issue number12
DOIs
StatePublished - Jun 15 2008
Externally publishedYes

Fingerprint

Angiopoietin-1
Asthma
Inflammation
Ovalbumin
Angiopoietins
Lung
Anti-Inflammatory Agents
Respiratory Physiological Phenomena
Interleukin-13
Vascular Cell Adhesion Molecule-1
Interleukin-5
Capillary Permeability
Blood Vessels
Intercellular Signaling Peptides and Proteins
Animal Models
Phosphorylation

Keywords

  • Airway resistance
  • Eotaxin
  • Interleukin 5
  • Nuclear factor-κB
  • VCAM-1

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. / Simoes, Davina C.M.; Vassilakopoulos, Theodoros; Toumpanakis, Dimitrios; Petrochilou, Kalomira; Roussos, Charis; Papapetropoulos, Andreas.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 177, No. 12, 15.06.2008, p. 1314-1321.

Research output: Contribution to journalArticle

Simoes, Davina C.M. ; Vassilakopoulos, Theodoros ; Toumpanakis, Dimitrios ; Petrochilou, Kalomira ; Roussos, Charis ; Papapetropoulos, Andreas. / Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. In: American Journal of Respiratory and Critical Care Medicine. 2008 ; Vol. 177, No. 12. pp. 1314-1321.
@article{4b15e21890024bda920d9af5c8433376,
title = "Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma",
abstract = "Rationale: The angiopoietins (Ang) comprise a family of growth factors mainly known for their role in blood vessel formation and remodeling. The best-studied member, Ang-1, exhibits antiapoptotic and antiinflammatory effects. Although the involvement of Ang-1 in angiogenesis is well recognized, little information exists about its role in respiratory physiology and disease. On the basis of its ability to inhibit vascular permeability, adhesion molecule expression, and cytokine production, we hypothesized that Ang-1 administration might exert a protective role in asthma. Objectives: To determine changes in the expression of Ang and to assess the ability of Ang-1 to prevent the histologic, biochemical,and functional changes observed in an animal model of asthma. Methods: To test our hypothesis, a model of allergic airway disease that develops after ovalbumin (OVA) sensitization and challenge was used. Measurements and Main Results: Ang-1 expression was reduced at the mRNA and protein levels in lung tissue of mice sensitized and challenged with OVA, leading to reduced Tie2 phosphorylation. Intranasal Ang-1 treatment prevented the OVA-induced eosinophilic lung infiltration, attenuated the increase in IL-5 and IL-13, and reduced eotaxin and vascular cell adhesion molecule 1 expression. These antiinflammatory actions of Ang-1 coincided with higher levels of IκB and decreased nuclear factor-κB binding activity. More importantly, Ang-1 reversed the OVA-induced increase in tissue resistance and elastance, improving lung function. Conclusions: We conclude that Ang-1 levels are decreased in asthma and that administration of Ang-1 might be of therapeutic value because it prevents the increased responsiveness of the airways to constrictors and ameliorates inflammation.",
keywords = "Airway resistance, Eotaxin, Interleukin 5, Nuclear factor-κB, VCAM-1",
author = "Simoes, {Davina C.M.} and Theodoros Vassilakopoulos and Dimitrios Toumpanakis and Kalomira Petrochilou and Charis Roussos and Andreas Papapetropoulos",
year = "2008",
month = "6",
day = "15",
doi = "10.1164/rccm.200708-1141OC",
language = "English (US)",
volume = "177",
pages = "1314--1321",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "12",

}

TY - JOUR

T1 - Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma

AU - Simoes, Davina C.M.

AU - Vassilakopoulos, Theodoros

AU - Toumpanakis, Dimitrios

AU - Petrochilou, Kalomira

AU - Roussos, Charis

AU - Papapetropoulos, Andreas

PY - 2008/6/15

Y1 - 2008/6/15

N2 - Rationale: The angiopoietins (Ang) comprise a family of growth factors mainly known for their role in blood vessel formation and remodeling. The best-studied member, Ang-1, exhibits antiapoptotic and antiinflammatory effects. Although the involvement of Ang-1 in angiogenesis is well recognized, little information exists about its role in respiratory physiology and disease. On the basis of its ability to inhibit vascular permeability, adhesion molecule expression, and cytokine production, we hypothesized that Ang-1 administration might exert a protective role in asthma. Objectives: To determine changes in the expression of Ang and to assess the ability of Ang-1 to prevent the histologic, biochemical,and functional changes observed in an animal model of asthma. Methods: To test our hypothesis, a model of allergic airway disease that develops after ovalbumin (OVA) sensitization and challenge was used. Measurements and Main Results: Ang-1 expression was reduced at the mRNA and protein levels in lung tissue of mice sensitized and challenged with OVA, leading to reduced Tie2 phosphorylation. Intranasal Ang-1 treatment prevented the OVA-induced eosinophilic lung infiltration, attenuated the increase in IL-5 and IL-13, and reduced eotaxin and vascular cell adhesion molecule 1 expression. These antiinflammatory actions of Ang-1 coincided with higher levels of IκB and decreased nuclear factor-κB binding activity. More importantly, Ang-1 reversed the OVA-induced increase in tissue resistance and elastance, improving lung function. Conclusions: We conclude that Ang-1 levels are decreased in asthma and that administration of Ang-1 might be of therapeutic value because it prevents the increased responsiveness of the airways to constrictors and ameliorates inflammation.

AB - Rationale: The angiopoietins (Ang) comprise a family of growth factors mainly known for their role in blood vessel formation and remodeling. The best-studied member, Ang-1, exhibits antiapoptotic and antiinflammatory effects. Although the involvement of Ang-1 in angiogenesis is well recognized, little information exists about its role in respiratory physiology and disease. On the basis of its ability to inhibit vascular permeability, adhesion molecule expression, and cytokine production, we hypothesized that Ang-1 administration might exert a protective role in asthma. Objectives: To determine changes in the expression of Ang and to assess the ability of Ang-1 to prevent the histologic, biochemical,and functional changes observed in an animal model of asthma. Methods: To test our hypothesis, a model of allergic airway disease that develops after ovalbumin (OVA) sensitization and challenge was used. Measurements and Main Results: Ang-1 expression was reduced at the mRNA and protein levels in lung tissue of mice sensitized and challenged with OVA, leading to reduced Tie2 phosphorylation. Intranasal Ang-1 treatment prevented the OVA-induced eosinophilic lung infiltration, attenuated the increase in IL-5 and IL-13, and reduced eotaxin and vascular cell adhesion molecule 1 expression. These antiinflammatory actions of Ang-1 coincided with higher levels of IκB and decreased nuclear factor-κB binding activity. More importantly, Ang-1 reversed the OVA-induced increase in tissue resistance and elastance, improving lung function. Conclusions: We conclude that Ang-1 levels are decreased in asthma and that administration of Ang-1 might be of therapeutic value because it prevents the increased responsiveness of the airways to constrictors and ameliorates inflammation.

KW - Airway resistance

KW - Eotaxin

KW - Interleukin 5

KW - Nuclear factor-κB

KW - VCAM-1

UR - http://www.scopus.com/inward/record.url?scp=44949242413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949242413&partnerID=8YFLogxK

U2 - 10.1164/rccm.200708-1141OC

DO - 10.1164/rccm.200708-1141OC

M3 - Article

C2 - 18356565

AN - SCOPUS:44949242413

VL - 177

SP - 1314

EP - 1321

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 12

ER -